Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 128,058 shares at $26.59 ($3.5M) on 2018-01-16, disclosed to the SEC on 2018-01-18.
Open-market sale of $3.5M BHVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.59 | 37,033 | $985K | 28.5% |
| 2 | $27.07 | 1,834 | $50K | 1.4% |
| 3 | $26.19 | 23,726 | $621K | 18.0% |
| 4 | $26.84 | 37,530 | $1.0M | 29.2% |
| 5 | $26.71 | 4,546 | $121K | 3.5% |
| 6 | $27.87 | 5,618 |
| $157K |
| 4.5% |
| 7 | $28.71 | 17,671 | $507K | 14.7% |
| 8 | $29.22 | 100 | $3K | 0.1% |
| Total | $26.95 avg | 128,058 | $3.5M | 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2021-11-17 | $8.8M | — | Filing → |